Home » Topics » Regulatory » EMA

EMA
RSS

APR-246 receives European orphan drug designation

Jan. 23, 2015

EMA accepts AstraZeneca's lesinurad MAA for gout

Jan. 22, 2015

UCB confirms regulatory filings for antiepileptic drug brivaracetam

Jan. 22, 2015

EMA grants positive opinion for orphan drug status for enadenotucirev

Jan. 14, 2015

EMA accepts alirocumab MAA for review

Jan. 12, 2015

Celgene receives positive CHMP opinion to extend Revlimid indication

Dec. 24, 2014

EMA committee recommends approval of dalbavancin

Dec. 24, 2014

Xiapex receives positive opinion by CHMP for Peyronie's disease

Dec. 23, 2014

CHMP backs approval of Orexigen's naltrexone/bupropion for weight management

Dec. 22, 2014

EMA committee recommends approval of Xadago to treat mid- to late-stage Parkinson's disease

Dec. 22, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...